Patent Assignment
Reel/Frame 057438/0025
Merger
Recorded: 2021-09-08
Pages: 8
Assignor
VALO EARLY DISCOVERY, INC.
Executed: 2021-09-01
Assignee
VALO HEALTH, INC.
399 BOYLSTON STREET, SUITE 505, BOSTON, MASSACHUSETTS, 02116
Covered Properties
(108)
Inhibiting USP36
PCT:
PCT/US2020/030833 ↗
Inhibiting OTUB1
PCT:
PCT/US2020/030838 ↗
Inhibiting Trabid
PCT:
PCT/US2020/031214 ↗
Inhibiting USP19
PCT:
PCT/US2020/031608 ↗
Derivatives of Squaric Acid with Anti-Proliferative Activity
Pyrido [2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Raf Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Novel Compounds and Compositions for the Inhibition of Nampt
Piperidine Derivatives and Compositions for the Inhibition of Nicotinamide Phosphoribosyltransferase (Nampt)
Pyridinyl and Pyrimidinyl Sulfoxide and Sulfone Derivatives
Amido-Benzyl Sulfone and Sulfoxide Derivatives
Amido Spirocyclic Amide and Sulfonamide Derivatives
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
3-Spirocyclic-6-Hydroxamic Acid Tetralins as Hdac Inhibitors
3-Spiro-7-Hydroxamic Acid Tetralins as Hdac Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Amido Spirocyclic Amide and Sulfonamide Derivatives
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors
Thienopyridine Carboxamides as Ubiquitin-Specific Protease Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
Methods Using HDAC11 Inhibitors
Methods Using HDAC11 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Carboxamides as Ubiquitin-Specific Protease Inhibitors
Patent:
11,524,966 →
Application:
16/637,692 →
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Methods Using HDAC11 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Amido Spirocyclic Amide and Sulfonamide Derivatives
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Piperidine Derivatives and Compositions for the Inhibition of Nicotinamide Phosphoribosyltransferase (Nampt)
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Isoindolines as Hdac Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
17/161,324 →
Publication:
US 2021/0292337
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
17/179,046 →
Publication:
US 2021/0323978
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Inhibiting Deubiquitinase USP25 and USP28
Carboxamides as Ubiquitin-Specific Protease Inhibitors
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 25, 2007
From: MURTHI, KRISHNA K.; KOSTLER, ROLAND; SMITH, CHASE; BRANDSTETTER, TILMANN
To: GPC BIOTECH AG
Reel/Frame 019878/0970 →
Assignment of Assignor's Interest
Sep 28, 2009
From: MURTHI, KRISHNA; CASAUBON, REBECCA; KLUGE, ARTHUR F.; SMITH, CHASE
To: GPC BIOTECH, INC.
Reel/Frame 023302/0017 →
Assignment of Assignor's Interest
Sep 28, 2009
From: GPC BIOTECH AG; GPC BIOTECH, INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 023301/0352 →
Assignment of Assignor's Interest
Sep 28, 2009
From: GPC BIOTECH AG; GPC BIOTECH, INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 023298/0850 →
Assignment of Assignor's Interest
Feb 21, 2012
From: FORMA THERAPEUTICS, INC
To: FORMA TM LLC
Reel/Frame 027733/0930 →
Assignment of Assignor's Interest
Jun 19, 2012
From: GPC BIOTECH AG; GPC BIOTECH INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 028402/0804 →
Assignment of Assignor's Interest
Jun 19, 2012
From: NEUMAN, LARS; EICKHOFF, JAN; HANNUS, STEFAN; SCHOOP, ANDREAS
To: GPC BIOTECH AG
Reel/Frame 028562/0384 →
Assignment of Assignor's Interest
Jun 19, 2012
From: MURTHI, KRISHNA; CASAUBON, REBECCA; KLUGE, ARTHUR F; SMITH, CHASE C
To: GPC BIOTECH AG; GPC BIOTECH INC
Reel/Frame 028402/0656 →
Assignment of Assignor's Interest
Mar 24, 2015
From: BAIR, KENNETH W.; BAUMEISTER, TIMM R.; ZHENG, XIAOZHANG
To: FORMA THERAPEUTICS, INC.
Reel/Frame 035238/0637 →
Assignment of Assignor's Interest
Mar 24, 2015
From: PHARMARON, INC.
To: GENENTECH, INC.
Reel/Frame 035239/0201 →
Assignment of Assignor's Interest
Mar 24, 2015
From: PHARMARON BEIJING, CO., LTD.
To: PHARMARON, INC.
Reel/Frame 035239/0167 →
Assignment of Assignor's Interest
Mar 24, 2015
From: LIU, XIONGCAI; YUEN, PO-WAI; ZHANG, YAMIN
To: PHARMARON BEIJING, CO., LTD.
Reel/Frame 035239/0105 →
Assignment of Assignor's Interest
Mar 24, 2015
From: DRAGOVICH, PETER; PATEL, SNAHEL; ZAK, MARK; ZHAO, GUILING
To: GENENTECH, INC.
Reel/Frame 035239/0035 →
Assignment of Assignor's Interest
Mar 24, 2015
From: FORMA THERAPEUTICS, INC.
To: FORMA TM, LLC
Reel/Frame 035238/0913 →
Assignment of Assignor's Interest
Jan 19, 2016
From: IOANNIDIS, STEPHANOS; TALBOT, ADAM CHARLES; FOLLOWS, BRUCE; BUCKMELTER, ALEXANDRE JOSEPH
To: FORMA THERAPEUTICS, INC.
Reel/Frame 037523/0395 →
Assignment of Assignor's Interest
Jan 19, 2016
From: IOANNIDIS, STEPHANOS; TALBOT, ADAM CHARLES; FOLLOWS, BRUCE; BUCKMELTER, ALEXANDRE JOSEPH
To: FORMA THERAPEUTICS, INC.
Reel/Frame 037523/0344 →
Assignment of Assignor's Interest
Apr 20, 2016
From: ZHENG, XIAOZHANG; NG, PUI YEE; RUDNITSKAYA, ALEKSANDRA; LANCIA, DAVID R., JR.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 038331/0802 →
Assignment of Assignor's Interest
Apr 20, 2016
From: ZHENG, XIAOZHANG; NG, PUI YEE; HAN, BINGSONG; THOMASON, JENNIFER R.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 038331/0965 →
Assignment of Assignor's Interest
Dec 15, 2016
From: BAIR, KENNETH W; BAUMEISTER, TIMM R; BUCKMELTER, ALEX J; CLODFELTER, KARL H
To: FORMA THERAPEUTICS, INC.
Reel/Frame 040993/0159 →
Assignment of Assignor's Interest
Dec 15, 2016
From: FORMA THERAPEUTICS, INC.
To: FORMA TM, LLC
Reel/Frame 040940/0704 →
Assignment of Assignor's Interest
Dec 15, 2016
From: BAIR, KENNETH W; BAUMEISTER, TIMM R; BUCKMELTER, ALEX J; CLODFELTER, KARL H
To: FORMA THERAPEUTICS, INC.
Reel/Frame 040740/0308 →
Assignment of Assignor's Interest
Mar 24, 2017
From: ZHENG, XIAOZHANG; NG, PUI YEE; HAN, BINGSONG; THOMPSON, JENNIFER R.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 041731/0502 →
Corrective Assignment to Correct the Fourth Inventor Last Name and the Tenth Inventor's Middle Initial Previously Recorded on Reel 041731 Frame 0502. Assignor(S) Hereby Confirms the Assignment.
Sep 22, 2017
From: ZHENG, XIAOZHANG; NG, PUI YEE; HAN, BINGSONG; THOMASON, JENNIFER R.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 043952/0308 →
Assignment of Assignor's Interest
Dec 6, 2017
From: DAVIS, HEATHER
To: FORMA THERAPEUTICS, INC.
Reel/Frame 044311/0148 →
Assignment of Assignor's Interest
Oct 29, 2018
From: ZHENG, XIAOZHANG; NG, PUI YEE; HAN, BINGSONG; THOMASON, JENNIFER R.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 047343/0909 →